[go: up one dir, main page]

WO1994025600A1 - Antigenes recombines du virus ourlien et leur utilisation dans les vaccins - Google Patents

Antigenes recombines du virus ourlien et leur utilisation dans les vaccins Download PDF

Info

Publication number
WO1994025600A1
WO1994025600A1 PCT/EP1994/001297 EP9401297W WO9425600A1 WO 1994025600 A1 WO1994025600 A1 WO 1994025600A1 EP 9401297 W EP9401297 W EP 9401297W WO 9425600 A1 WO9425600 A1 WO 9425600A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
die
designated
membrane anchor
vector
Prior art date
Application number
PCT/EP1994/001297
Other languages
English (en)
Inventor
Alex Bollen
Sophie Houard
Erling Carl Jacob Norrby
Tamas Mark Varsanyi
Original Assignee
Smithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.
Priority to KR1019950704819A priority Critical patent/KR960702000A/ko
Priority to AU69648/94A priority patent/AU6964894A/en
Priority to EP94915539A priority patent/EP0695358A1/fr
Priority to JP6523863A priority patent/JPH08512199A/ja
Publication of WO1994025600A1 publication Critical patent/WO1994025600A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the cDNA module (1701 bp) encoding the FS + a + protein was recovered by cleavage with enzymes S al and Ahai ⁇ and introduced into the S al site of the vaccinia transfer vector pULB5213, which is a derived of the standard vaccinia vector pSCl 1 (Chakrabati ej aL 1985, Molecular and Cellular Biology 5, 3403-3409).
  • the resutling plasmid, pNIV3205 is illustrated in Fig. IB.
  • This cDNA was then amplified by PCR with two sets of primers to generate a first double stranded cDNA fragment corresponding to bases 79 to 629 of the HNmRNA (primers pHN-13 and EcoHNMl) and a second one spanning bases 603 to 1005 (primers EcoHNM2 and pH982).
  • the s+FHNa- protein has been detected in d e spent culture medium by immunoprecipitation using a rabbit polyclonal antibody raised against die purified mumps virion; it appeared as a 84 KDa monomer.
  • VV3205 F protein 80 44.4% (4 surv. 9 challenged)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne de l'ADN recombiné codant un antigène du virus ourlien choisi dans le groupe contenant: (a) la protéine de fusion pleine longeur (F) complétée par un (des) peptide(s) de signal et le domaine d'ancrage membranaire (a) (désigné ici par Fs+a+); la protéine de fixation pleine longueur ou l'hémagglutinine-neuraminidase (HN); la protéine de nucléocapside pleine longueur (NP); (b) la protéine de fusion tronquée exempte de domaine d'ancrage membranaire (désignée ici par Fs+a-); (c) une protéine hybride dérivée par fusion des protéines F, HN et/ou NP ou des parties de celles-ci. L'invention porte également sur des vecteurs comprenant l'ADN selon l'invention ainsi qu'un hôte tel que le virus de la vaccine, une cellule mammifère ou une cellule bactérienne transformée ou transfectée avec le vecteur, et sur les protéines exprimées par les hôtes.
PCT/EP1994/001297 1993-04-30 1994-04-26 Antigenes recombines du virus ourlien et leur utilisation dans les vaccins WO1994025600A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
KR1019950704819A KR960702000A (ko) 1993-04-30 1994-04-26 귀밑샘염 바이러스로부터의 재조합 항원 및 백신에서의 이것의 사용방법(recombinant antigens from mumps virus and their use in vaccines)
AU69648/94A AU6964894A (en) 1993-04-30 1994-04-26 Recombinant antigens from mumps virus and their use in vaccines
EP94915539A EP0695358A1 (fr) 1993-04-30 1994-04-26 Antigenes recombines du virus ourlien et leur utilisation dans les vaccins
JP6523863A JPH08512199A (ja) 1993-04-30 1994-04-26 ムンプスウイルス由来の組換え抗原およびワクチンにおける使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939308963A GB9308963D0 (en) 1993-04-30 1993-04-30 Novel compounds
GB9308963.9 1993-04-30

Publications (1)

Publication Number Publication Date
WO1994025600A1 true WO1994025600A1 (fr) 1994-11-10

Family

ID=10734747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/001297 WO1994025600A1 (fr) 1993-04-30 1994-04-26 Antigenes recombines du virus ourlien et leur utilisation dans les vaccins

Country Status (8)

Country Link
EP (1) EP0695358A1 (fr)
JP (1) JPH08512199A (fr)
KR (1) KR960702000A (fr)
CN (1) CN1126492A (fr)
AU (1) AU6964894A (fr)
CA (1) CA2161645A1 (fr)
GB (1) GB9308963D0 (fr)
WO (1) WO1994025600A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004382A3 (fr) * 1994-07-29 1996-03-21 Chiron Corp Proteines virales secretees utiles pour les vaccins et les diagnostics
WO1998040492A1 (fr) * 1997-03-11 1998-09-17 Cambridge Genetics Limited Compositions et methodes d'elimination de cellules indesirables
WO1998052603A3 (fr) * 1997-05-23 1999-05-14 Schweiz Serum & Impfinst Vaccin comprenant de l'adn a enveloppe du virus de la grippe
WO2000018929A3 (fr) * 1998-09-25 2000-11-09 Smithkline Beecham Biolog Nouveaux composés
CN1843507B (zh) * 2006-02-14 2010-04-21 中国医学科学院医学生物学研究所 一种人用腮腺炎病毒组份疫苗及其制备方法和应用
WO2021119497A1 (fr) * 2019-12-11 2021-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogènes des virus des oreillons et de la rougeole et utilisation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106290862B (zh) * 2016-08-05 2017-10-31 北京市华信行生物科技有限公司 腮腺炎病毒hn抗原及其在检测抗腮腺炎病毒抗体中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011534A1 (fr) * 1988-05-24 1989-11-30 Board Of Regents, The University Of Texas System Hemagglutinine-neuraminidase du virus des oreillons

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011534A1 (fr) * 1988-05-24 1989-11-30 Board Of Regents, The University Of Texas System Hemagglutinine-neuraminidase du virus des oreillons

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KYOSHI TANABAYASHI ET AL.: "Expression of Mumps virus glycoproteins in mammalian cells from cloned cDNAs: Both F and HN proteins are required for cell fusion", VIROLOGY, vol. 187, no. 2, April 1992 (1992-04-01), pages 801 - 804 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100064A (en) * 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
WO1996004382A3 (fr) * 1994-07-29 1996-03-21 Chiron Corp Proteines virales secretees utiles pour les vaccins et les diagnostics
WO1998040492A1 (fr) * 1997-03-11 1998-09-17 Cambridge Genetics Limited Compositions et methodes d'elimination de cellules indesirables
US7846429B2 (en) 1997-03-11 2010-12-07 Mayo Foundation For Medical Education And Research Compositions and methods for elimination of unwanted cells
WO1998052603A3 (fr) * 1997-05-23 1999-05-14 Schweiz Serum & Impfinst Vaccin comprenant de l'adn a enveloppe du virus de la grippe
WO2000018929A3 (fr) * 1998-09-25 2000-11-09 Smithkline Beecham Biolog Nouveaux composés
CN1843507B (zh) * 2006-02-14 2010-04-21 中国医学科学院医学生物学研究所 一种人用腮腺炎病毒组份疫苗及其制备方法和应用
WO2021119497A1 (fr) * 2019-12-11 2021-06-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogènes des virus des oreillons et de la rougeole et utilisation

Also Published As

Publication number Publication date
CA2161645A1 (fr) 1994-11-10
EP0695358A1 (fr) 1996-02-07
KR960702000A (ko) 1996-03-28
GB9308963D0 (en) 1993-06-16
JPH08512199A (ja) 1996-12-24
AU6964894A (en) 1994-11-21
CN1126492A (zh) 1996-07-10

Similar Documents

Publication Publication Date Title
CA2031164C (fr) Herpesvirus recombinant de dindons et vaccins de vecteur vivant qui en sont derives
US5242829A (en) Recombinant pseudorabies virus
KR970011149B1 (ko) 재조합 아비폭스 바이러스
KR0166585B1 (ko) 앵커-결여 vzv 당단백질, 이를 제조하는 방법 및 이의 면역보호적 용도
US5021347A (en) Recombinant vaccinia virus expressing E-protein of Japanese encephalitis virus
WO1994017810A1 (fr) Vaccin recombine contre le cytomegalovirus
HK1006468B (en) Novel compounds
US4810492A (en) Flavivirus antigen
EP0510773B1 (fr) Vaccin de sous-unités contre le coronavirus canin
JPH08173171A (ja) ヒト呼吸器系ウイルス用ワクチン
EP0538341B1 (fr) Vaccin a base de glycoproteine de vhe-4 (virus d'herpes equin-4)
Kit et al. Modified-live infectious bovine rhinotracheitis virus vaccine expressing monomer and dimer forms of foot-and-mouth disease capsid protein epitopes on surface of hybrid virus particles
CA2156423A1 (fr) Virus recombinants de molluscum contagiosum et leurs utilisations
EP0695358A1 (fr) Antigenes recombines du virus ourlien et leur utilisation dans les vaccins
Ray et al. Expression of the fusion glycoprotein of human parainfluenza type 3 virus in insect cells by a recombinant baculovirus and analysis of its immunogenic property
EP0423869B1 (fr) Vaccin contre le virus de la bronchite infectieuse (IBV)
EP0606452A1 (fr) Vaccins vecteurs d'herpesvirus felin recombine
US5925358A (en) Recombinant fowlpox viruses and uses thereof
WO1995009249A1 (fr) Vaccination per os des mammiferes
US5486473A (en) A DNA coding for a Flavivirus antigen
US5674735A (en) DNA encoding the EHV-4 gH or gC glycoprotein
AU634512B2 (en) Expression of the plasmodium circumsporozoite protein in insect cells
DK175980B1 (da) Recombinante vacciniavira og anvendelsen af samme
NZ259362A (en) Varicella zoster virus immediate early protein 175 (vzv iep 175) and derivatives, its production and use
WO1994000587A2 (fr) Herpesvirus-4 equin attenue utilise comme vaccin vivant ou vecteur recombine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 94192620.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN JP KR NZ SI US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994915539

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 291162

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2161645

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1994915539

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1996 535242

Country of ref document: US

Date of ref document: 19960318

Kind code of ref document: A

WWW Wipo information: withdrawn in national office

Ref document number: 1994915539

Country of ref document: EP